ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, tyrosine kinase inhibitors (TKI) targeting oncogenes such as cABL (activated in Philadelphia chromosome-positive chronic myeloid leukemia, CML)1, BRAF (activated in melanoma)2, ERBB2 (activated in a fraction of breast cancers)3, EGFR (activated in a sizable portion of non-small cell lung cancers, NSCLC)4, KIT (activated in gastrointestinal stromal tumors, GIST)5, or VGFR (activated in renal cancers and others)6, have been approved for the routine treatment of cancer patients.